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ABSTRACT: At the surface of dendritic cells, C-type lectin
receptors (CLRs) allow the recognition of carbohydrate-based
PAMPS or DAMPS (pathogen- or danger-associated molecular
patterns, respectively) and promote immune response
regulation. However, some CLRs are hijacked by viral and
bacterial pathogens. Thus, the design of ligands able to target
speciﬁcally one CLR, to either modulate an immune response
or to inhibit a given infection mechanism, has great potential
value in therapeutic design. A case study is the selective
blocking of DC-SIGN, involved notably in HIV trans-infection
of T lymphocytes, without interfering with langerin-mediated
HIV clearance. This is a challenging task due to their
overlapping carbohydrate speciﬁcity. Toward the rational
design of DC-SIGN selective ligands, we performed a comparative aﬃnity study between DC-SIGN and langerin with natural
ligands. We found that GlcNAc is recognized by both CLRs; however, selective sulfation are shown to increase the selectivity in
favor of langerin. With the combination of site-directed mutagenesis and X-ray structural analysis of the langerin/GlcNS6S
complex, we highlighted that 6-sulfation of the carbohydrate ligand induced langerin speciﬁcity. Additionally, the K313 residue
from langerin was identiﬁed as a critical feature of its binding site. Using a rational and a diﬀerential approach in the study of CLR
binding sites, we designed, synthesized, and characterized a new glycomimetic, which is highly speciﬁc for DC-SIGN vs langerin.
STD NMR, SPR, and ITC characterizations show that compound 7 conserved the overall binding mode of the natural
disaccharide while possessing an improved aﬃnity and a strict speciﬁcity for DC-SIGN
C-type lectin receptors (CLRs) are central sensing systemsfor the regulation of the initial immune response through
dendritic cells.1,2 Together with the toll-like receptor (TLR)
family of pathogen recognition receptors (PRRs), they are key
elements in the recognition of both pathogen-associated
molecular patterns (PAMPs) and danger-associated molecular
patterns (DAMPs) displayed by altered cells. Dendritic cells use
CLRs to recognize carbohydrate-based PAMPs or DAMPs in a
Ca2+-dependent manner. Upon recognition, and depending on
the crosstalk with TLRs, an activation or tolerance response will
be promoted by dendritic cells toward speciﬁc T-cells.3,4 Apart
from being essentials for immune regulation, some of these
CLRs are also hijacked by pathogens during their infection
process. For instance, LSECtin and DC-SIGN are used to this
purpose respectively by the Ebola virus and by a wide range of
virus and bacterial pathogens (from HIV, M. tuberculosis, to C.
albicans for DC-SIGN).5−9 Thus, CLRs have become attractive
targets for the design of new ligands able to modulate the
immune response toward activation or inhibition as a function
of the CLRs addressed. Such ligands could become anti-
infective agents in cases where CLRs are used by pathogens to
infect the host.
The development of such ligands as molecular probes for the
modulation of various CLRs is the subject of intense
eﬀorts.10−12 However, the development of highly speciﬁc and
eﬀective ligands toward CLRs faces several speciﬁc bottlenecks.
The ﬁrst problem is the nature of the natural ligands,
oligosaccharides, that are easily metabolized and that may
have a low level of bioavailability under therapeutic conditions.
Second, natural carbohydrates frequently bind within CLRs’
Ca2+ binding sites using multiple binding modes, thus making
the speciﬁc beneﬁt of any targeted modiﬁcation almost
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unpredictable. Indeed, depending on the mode of binding, a
given structural modiﬁcation of a ligand may either improve or
reduce and even eliminate the binding aﬃnity. Third, the active
sites of CLRs are shallow binding pockets and open to the
solvent (Figure 1A), contributing to low aﬃnity ligands, often
in the millimolar range. And ﬁnally, designed ligands often
generate oﬀ-target eﬀects due to carbohydrate cross-recognition
between various CLRs. Altogether, these barriers make the
rational design of tightly bound and CLR-selective ligands
diﬃcult. Despite these challenges, methods in carbohydrate
chemistry and structure-based design have progressed, opening
the door to successes in CLR ligand design.
DC-SIGN, one of the most investigated CLRs up to now, is a
good example of the cumulative diﬃculties typically encoun-
tered with CLRs. To date, issues involving biostability and
bioavailability,13−16 heterogeneous modes of binding with the
Ca2+ binding site, and weak protein−carbohydrate aﬃnity have
been successfully addressed for DC-SIGN by several
groups.13,17−19 Our previous work set out to rationally design
glycosidase-resistant glycomimetic ligands that bound to DC-
SIGN with binding modes similar to the natural ligands. From
this approach, we identiﬁed two glycomimetics, a pseudodi- and
a pseudotrisaccharide, as lead compounds able to bind
eﬃciently DC-SIGN and even to be eﬀective in anti-HIV
trans-infection test (Figure 1B).20−22 However, because of the
unpredictable multiple binding mode of carbohydrates with
CLRs,23−25 we have been able to establish that only the
pseudodisaccharide 1 meets the requirement of a unique
binding mode within DC-SIGN (Figure 1C) and allows further
rational molecule improvement.
Using structural information regarding the binding mode of
this glycomimetic,23 we rationally improved the relative aﬃnity
of compound 1 for DC-SIGN by substituting the methyl ester
groups on the cyclohexane moiety with the amides in
compound 2. The extended ligand surface contact within the
binding site leads to an improvement of its aﬃnity.26 Other
groups, also using structural information and molecular
modeling, have been successful in aﬃnity improvement of
monovalent ligands.15,27,28 However, further aﬃnity improve-
ments in the low micromolar or even the nanomolar ranges
have been reached only using multivalent presentations of lead
ligands on molecular scaﬀolds.18,29−32 On the other hand, the
carbohydrate cross-recognition between diﬀerent CLRs has not
been addressed speciﬁcally up to now. During the development
of compound 2, we discovered a fortuitous selectivity increase
in favor of DC-SIGN relative to langerin, another CLR also
able to recognize HIV envelope glycoprotein, gp120.23,26
However, even if some selectivity could be obtained, the
remaining activity toward langerin is not negligible, particularly
in a multivalent presentation that will also improve this
nondesired interaction. The case study of DC-SIGN and
langerin is of particular interest due to their opposite
physiological consequences, respectively as promoting the T-
lymphocytes infection or contributing to virus elimina-
tion.7,33−35 In addition, langerin targets HIV to Birbeck
granules, which are believed to be an atypical antigen
processing pathway to Langerhans cells.33,36 For all of these
reasons, the design of speciﬁc and selective antagonists for DC-
SIGN over langerin is fully justiﬁed.
Here, in this work, we address speciﬁcally the unsolved
problem of CLR cross-recognition. We pioneer a diﬀerential
rational design approach by which we analyze the structural and
functional variances between the two binding sites, developing
ligands that favor DC-SIGN and disfavor recognition by
langerin. Diﬀerential rational design aims to reach a complete
speciﬁcity for DC-SIGN. Here, the DC-SIGN/langerin pair is
used as a case study for potential applications in the design of
HIV capture inhibitors and of immune regulation therapeutics.
■ RESULTS
Sulfation-Induced Selectivity toward Langerin. The
main diﬀerence in ligand recognition between DC-SIGN and
langerin lies in the ability of langerin to speciﬁcally recognize
sulfated glycans. In order to design ligand modiﬁcations to
generate speciﬁc glycomimetic candidates, recognition of
sulfated glycans by langerin needs to be understood. Langerin
recognizes sulfated glycans with terminal 6-SO4−Gal resi-
dues37,38 or glycosaminoglycans containing sulfated derivatives
of N-acetyl-D-glucosamine (GlcNAc).39,40 Because GlcNAc and
Man share the same 3,4-diequatorial hydroxyl groups for
Figure 1. Structural comparison and glycomimetic design targeting the carbohydrate binding domain of DC-SIGN vs langerin. (A) Surface
representation of DC-SIGN CRD (cyan, PDB 2it6) and langerin CRD (yellow, PDB 3c22). Ca2+ ions within the binding site are in pink. The two
langerin speciﬁc lysines, K299 and K313, are represented in dark blue. (B) Structure of two generations of glycomimetic directed against DC-SIGN.
(C and D). Electrostatic surfaces of DC-SIGN CRD in complex with 1 (PDB 2xr5) and 2 (STD NMR and molecular docking).
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binding to Ca2+, the binding mode of GlcNAc derivatives is
expected to be similar to that of Man. Thus, we focused our
selectivity characterization on GlcNAc-sulfated derivatives in
order to compare and transfer newly identiﬁed features to the
mannose-based glycomimetic lead compound 1.
The diﬀerent sulfated versions of N-acetyl-D-glucosamine
evaluated for their relative aﬃnity (IC50) for DC-SIGN and
langerin are presented in Figure 2A, B, and C. Nonsulfated
GlcNAc has the same aﬃnity for both lectins (5 mM, Figure 2C
and Table S2 in the Supporting Information) and comparable
with the reported aﬃnity of mannose for DC-SIGN.21
However, adding one or several negative sulfate groups onto
the ligand results in an increase in aﬃnity in favor of langerin,
while recognition by DC-SIGN drastically decreases. This
results in a selectivity factor of 5000 in favor of langerin as
measured for the disulfated ligand, GlcNS6S. Signiﬁcantly, a
single sulfation at position 6 of GlcNAc is responsible for a
selectivity factor close to 600 (IC50 of 0.39 mM and 0.22 mM
for GlcNAc6S and GlcNS6S, respectively).
Recognition Mechanism of Sulfated Ligands. The
interaction of sulfated saccharides is a unique feature of langerin
compared to DC-SIGN. To understand determinants of this
speciﬁcity, we analyzed the aﬃnities of sulfated ligands with two
active site mutants of the langerin-extracellular domain (Lg-
ECD). We studied the roles of lysines 299 and 313 (Figure
1A), which are ideally positioned in the Ca2+ site surroundings.
Figure 2D summarizes the IC50, determined by SPR inhibition
assay, for each ligand as a function of the Lg-ECD mutations.
Lysine mutations induce an overall decrease in aﬃnity of the
sulfated ligand for langerin (Figure 2D and Table S2). Mutation
K313A completely abolishes the improved aﬃnity observed
upon sulfation of the ligands. In addition, the K299A mutation
leads to a 2-fold reduction in GlcNAc6S ligand IC50 when
compared to wild type langerin. This eﬀect is more pronounced
for the K313A mutant, with a decrease of the aﬃnity of
GlcNAc6S for langerin by a factor of 10. The key role of lysine
313 is also observed in the crystallographic structure of the Lg-
carbohydrate recognition domain (CRD) with GlcNS6S.
X-ray Crystal Structure of Lg-CRD/GlcNS6S Complex.
The crystal contains four copies of the CRD per asymmetric
unit within a P42 space group. The structure solved at 1.89 Å is
well conserved when compared to previously determined
structures of Lg-CRD as illustrated by RMSDs of 0.443, 0.335,
and 0.331 Å with Lg-CRD structures without a ligand or
complexed with 6SO4−Galß1−4GlcNAC or Manα1−2Man
(PDB codes are 3c22, 3p5i, and 3p5f, respectively).38,41 As
structure resolution was conducted by molecular replacement
using an unliganded Lg-CRD model, the identiﬁcation of a
well-deﬁned electron density onto the Ca2+ ion allowed clear
establishment of the presence of the GlcNS6S ligand within the
binding site (Figure 3A). As expected, GlcNS6S binds to the
Ca2+ ion with its equatorial 3-OH and 4-OH groups. The
anomeric OH group interacts with K299. Pertaining to the
sulfate groups, the 6-sulfate is involved in an electrostatic
interaction with K313, and the N-sulfate in C2 is oriented
toward the solvent (Figure 3B). In addition, three water
molecules connect the ligand to the protein (see Supporting
Information, Figure S1).
It appears that K299 has a minor role in the binding whereas
the K313 plays a preponderant role in the aﬃnity of 6-sulfated
ligands (Figure 3C), in agreement with the impact of K313A
mutation reported above. However, both lysines contribute to
the establishment of a strong positive electrostatic region,
adjacent to the Ca2+ binding site, that allows to accommodate
diverse sulfated glycans (Figure 3C). For instance, in the
binding mode of 6SO4−Galß1−4GlcNac, the sulfate group of
Gal6S was clearly oriented between K313 and K299. In that
case, the two lysines were both essential to the sulfate
recognition.38,42,43 Recently, we characterized the binding
mode to Lg-CRD of eight heparin-derived trisaccharides,
composed of GlcN−IdoA−GlcN, with diﬀerent sulfation
patterns.40 In all cases, it is the terminal nonreducing GlcN
that is binding to the Ca2+ ion. The IdoA and GlcN residues
extend between K313 and K299 and establish secondary
contacts with the langerin surface. Here, it emerges that these
two lysines are dynamic in their interactions with the sulfate
group. Notably, K313 can shift to accommodate various
sulfated ligands (see SI Figure S2).
Aiming to develop a highly speciﬁc antagonist of DC-SIGN
versus langerin, the observation that a negative charge on the
sugar C6 speciﬁcally interacts with K313 of the langerin binding
site represents the starting point for a glycomimetic design
Figure 2. Inhibition of DC-SIGN and langerin binding to Man-BSA by
sulfated derivatives of GlcNAc in a SPR competition assay. (A)
Structure of GlcNAc-sulfated derivatives used in the study. (B)
Inhibition curves for DC-SIGN (left) and langerin (right). (C)
Comparison of IC50, extracted from B, for DC-SIGN (blue) or
langerin (red), as a function of the sulfation degree and position. (D)
Impact of lysine mutations in langerin on the IC50 of GlcNAc sulfated-
derivatives. IC50, extracted from SPR derived inhibitions curves, is
presented as a function of the GlcNAc sulfation pattern and for a given
version of langerin (see SI Material and Methods for corresponding
sensorgrams and inhibitory curves). (*) For GlcNS6S, the IC50 for
DC-SIGN has not been reached experimentally (see from B) and thus
extrapolated from the inhibition curve equation.
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strategy. The X-ray structure of the DC-SIGN complex with
glycomimetic 123 shows that the C6 position of the sugar unit is
not involved in any direct interaction (Figure 1C), and it is
located in a very open area, close to a negatively charged patch
of the DC-SIGN surface. A positive charge and/or a steric
hindrance in position C6 of 1 should lead to an electrostatic
repulsion or steric clashes with K313 within the langerin
binding site. Glycomimetics modiﬁed in position C6 are
expected to diﬀerentially impact binding to langerin and to
DC-SIGN.
DC-SIGN vs Langerin Selectivity of Pseudodisacchar-
ide Mimetics: Design of Third-Generation Ligand 7. On
the basis of the lead compound 1, we synthesized a novel group
of four compounds modiﬁed at position 6 of the mannose ring
(compounds 3−6, Figure 4, see Supporting Information for
experimental details) and analyzed their DC-SIGN vs langerin
selectivity using SPR. SPR competition studies with compound
1 or its 6-amino counterpart, compound 3 (Table 1), clearly
showed a strong enhancement of DC-SIGN selectivity in
compound 3.
While the selectivity is a modest 1.54 for the initial lead 1,
compound 3 reaches a selectivity factor above 7. We also
observed that the relative aﬃnity for DC-SIGN was improved
(IC50 = 481 μM), compared to the lead compound 1 (IC50 =
956 μM). Thus, as expected, the positively charged amino
group results in an improvement of DC-SIGN aﬃnity and
selectivity.
The eﬀect of the 6-amino group in DC-SIGN binding was
analyzed using NMR transient methods (STD-NMR and
NOESY experiments for the complex and the free mimic).44
STD NMR consists of a selective irradiation of the receptor in
the presence of a ligand. If the ligand is bound to the receptor,
it will receive some magnetization transferred from the protein
in an amount that is dependent on the proximity of the
contact.44 Transfer NOE, performed in the presence of a small
amount of the receptor, relies on the larger correlation time
acquired by the ligand when it is forming part of the
macromolecular complex; this causes larger and faster NOE
eﬀects that are averaged across the signals of the free ligand
when the association−dissociation equilibrium is fast enough.44
The triazole modiﬁed analogs 1-T and 3-T (Figure 5) allow a
better dispersion of NMR signals but do not modify the
binding process and the geometry of the bound conforma-
tion.26 Indeed, this analysis strongly suggested that 1-T and 3-T
share a common binding mode with DC-SIGN (see Supporting
Information data). As discussed in the introduction, compound
2 had been previously selected as a ﬁrst optimization of 1, on
the basis of its relative DC-SIGN aﬃnity (3 times improvement
of the IC50).
26 Its binding mode to DC-SIGN, characterized by
STD NMR (Figure 1D),26 is also conserved, and the additional
hydroxymethylene-benzyl groups increase the surface contact
of the ligand within the DC-SIGN binding site. The langerin
screening reported in Table 1 shows an unexpected selectivity
improvement of 2 over 1 by a factor of 7. Thus, the third-
generation mimic 7, combining the two modiﬁcations of
second-generation 2 and 3 (Figure 4), was synthesized.
A quantitative STD-NMR analysis of 7-T was frustrated by
spectral congestion. Attempts to solve the signal overlap by
including a second 1H−13C transference after the STD module
using an HSQC to spread the peaks along a second dimension
were unsuccessful due to low signal. Thus, for the study of the
DC-SIGN interaction of 7-T, we rely only on the transfer NOE
data, obtained in the presence of DC-SIGN, reﬂecting the
structural properties of the bound conformation. Transfer
NOESY experiments clearly showed the exclusive NOE of the
extended conformation as for 3-T (Figure 5 and Figure S12, for
full spectrum, in Supporting Information); consequently, we
can assess that bound conformations of 3-T and 7-T are
equivalent.
Figure 3. Binding mode of GlcNS6S within langerin calcium binding site. (A) Electron density map for bound GlcNS6S. The bound ligand is shown
superimposed on the Fo−Fc electron density map contoured at 3σ. Bonds involved in Ca2+ binding are in black dashed line. (B) Interaction network
involved in GlcNS6S interaction. Black dashed line for polar interaction and green dashed line for ionic bond. (C) Electrostatic potential of Lg-CRD
surface in the Lg-CRD/GlcNS6S complex highlights the positive area around K313 and K299 positions.
Figure 4. Structure of 6-modiﬁed pseudodimannosides 3−7.
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SPR competition tests showed no major alteration of the
aﬃnity of 7 for DC-SIGN relative to 2 and 3 (Table 1, DC-
SIGN IC50 254 μM). However, the cumulative modiﬁcations
from 2 and 3 as assembled in 7 appeared to induce a drastic
synergistic eﬀect on selectivity against langerin. Indeed, no IC50
for 7 could be determined in the competition-langerin binding
assay, since no inhibition was observed in the concentration
range (up to 4.4 mM). Thus, no selectivity factor could be
calculated. Gratifyingly, these data suggest that binding to
langerin is excluded for 7.
To further illuminate this ﬁnding, we evaluated the level of
binding inhibition for both DC-SIGN and langerin using the
maximal concentration sustainable in the assay (4.4 mM) with
ligands from the natural ligand Manα1−2Man to the mimics 1,
2, 3, and 7 (Table 1). At this high concentration, compounds 2
and 3 inhibit langerin 36.3% and 41.9%, respectively, while the
DC-SIGN binding inhibition reaches almost 100% for both
ligands. Remarkably, compound 7 results in almost 100%
inhibition of DC-SIGN binding with no observed langerin
inhibition.
Characterizations of Compound 7 Binding Properties
to DC-SIGN. We further analyzed the interaction properties of
7 with DC-SIGN ECD by ITC. The pseudosaccharide 7 (4.7
mM) was titrated into lectin solution (566 μM). The ITC data
of the titration of 7 to DC-SIGN ECD conﬁrm the moderate
aﬃnity (Figure 6A). Fitting one binding site model to the data
with an assumed stoichiometry value n ﬁxed to 1 yielded a Kd of
171 ± 11 μM, which was in the same range as the apparent
aﬃnity determined by SPR competition assay (IC50 254 μM).
So far, the combination of the moderate aﬃnity and a low
molecular weight of these glycomimetics have precluded the
evaluation of a Kd by SPR in a direct interaction mode. In
addition, improvement of the aﬃnity, below millimolar range,
allows observation in real time of the glycomimetic binding on
a DC-SIGN ECD functionalized surface. The resulting Kd is
310 μM for compound 7 (Figure 6B). From these diﬀerent and
complementary analyses, an aﬃnity in the range of 250 μM can
be assumed for 7. The ITC analysis yielded a ΔH = −9.54 ±
0.26 kJ mol−1 and a TΔS = 11.9 kJ mol−1, leading to a ΔG of
−21.4 kJ mol−1. Thus, the binding mode of 7 is almost equally
enthalpically and entropically driven.
■ DISCUSSION AND CONCLUSIONS
CLRs are involved in numerous aspects of immune regulation,
and they have attracted great interest as targets for anti-infective
strategies, vaccine delivery, immune modulation, etc. However,
due to their large open binding sites, their low aﬃnity for their
natural ligands, and the carbohydrate cross-recognition between
some CLRs, the number of speciﬁc ligands is limited. Indeed,
when considering only computed druggability scores, most
CLRs were predicted to be challenging or even undruggable
targets.45 Despite this challenging task, recent progress has
been made toward deﬁning potent antagonists against CLRs,
such as DC-SIGN, Mincle, and DCIR.29,46,47 However, we are
still far from compounds with the required aﬃnity and the
relevant speciﬁcity to envision their use in clinical trials.
To address speciﬁc diﬃculties encountered regarding
selectivity, we deﬁned, in this work, a new strategy to improve
our rationally designed glycomimetics. DC-SIGN and langerin
are CLRs for which development of a highly speciﬁc antagonist
would be of great potential impact.48 The rational design of
compounds selective for DC-SIGN is very challenging due to
its very open binding site, which is diﬃcult to exploit (Figure
1C). Thus, instead of modifying the ligand by adding additional
Table 1. Evaluation of Glycomimetics Inhibition Potency Towards DC-SIGN and langerin (SPR)a
IC50 (μM) Inhibition (%) at 4.4 mM
compounds DC-SIGN langerin selectivity DC-SIGN langerin
Manα1−2Man 915 ± 25 1680 ± 61 1.83 89.8 74.6
1 956 ± 38 1474 ± 329 1.54 83.3 40.8
2 329 ± 5 2556 ± 610 7.76 99.6 36.3
3 481 ± 11 3440 ± 668 7.15 97.3 41.9
4 703 ± 29 1236 ± 215 1.75 n.d. n.d.
5 1235 ± 40 1933 ± 90 1.56 n.d. n.d.
6 1366 ± 81 4035 ± 145 2.95 n.d. n.d.
7 254 ± 5 >4400 n.a. 99.7 0
an.a., not applicable; n.d., not determined.
Figure 5. Triazole derivatives 1-T, 3-T, and 7-T formulas showing the
NOE between H1 from mannose and H3 equatorial of cyclohexyl
moiety characteristic of an extended geometry (top). Expansions of
NOESY (A, C, E) and transfer NOESY (B, D, F) experiments for 3-T
(A and B), 1-T (C and D), and 7-T (E and F). Cross-peaks
corresponding with the NOE between mannose anomeric proton
H1M and H3 equatorial of cyclohexyl are labeled (bottom). Peaks
belonging to the central cyclohexyl moiety of 7-T are negative
contrasting with 3-T and 1-T (see E). This behavior corresponds to a
large molecule and is a consequence of the introduction of two
additional benzyl groups.
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anchoring points within the targeted binding site, as in classical
approaches, we searched for optimizations within our
compounds that could impair their interaction within the
langerin binding site. In order to do this, we ﬁrst made a careful
comparative analysis of the binding mode of natural ligands
known to be speciﬁc for one of the two CLRs. Having deﬁned
the diﬀerential determinants between the CLR binding sites
and their natural ligands, we can more completely understand
the source of ligand selectivity. Indeed, we showed that residue
K313 in the langerin binding site strongly interacts with a
sulfate group at C6 of the carbohydrate ligands. Then, we
exploited this ﬁnding to introduce modiﬁcations that should
selectively alter langerin recognition, while maintaining tight
DC-SIGN binding. Exploiting the diﬀerences between both
CLR binding sites and rational designed ligand modiﬁcations,
this strategy succeeded in generating a highly speciﬁc
compound for DC-SIGN. Following the evolution of 1 to 2
and 3 and ﬁnally to 7, we have improved the selectivity with
compound 7 to such a level that neither the interaction nor the
selectivity factor with langerin are measurable. We can target
DC-SIGN speciﬁcity rather than selectivity with the new
compound developed in this work. Arguably, the structure of 7
and its DC-SIGN aﬃnity may still be far from ideal for a
potential drug. However, the strategy we used to develop it,
where ligand improvements can be obtained through diﬀer-
ential analysis between two competing receptors for a given
ligand, can be of general use in the development of inhibitors.
This approach is of particular interest when improvements in
ligand/target aﬃnity are limited by biophysical phenomena, as
in the case of CLRs. Once the selectivity is achieved, the
increase of aﬃnity can be then reached by avidity eﬀect through
multivalent displaying of glycomimetics. In order to conﬁrm the
translation of the selectivity achieved with 7 into a real
biological eﬀect, such multivalent systems presenting 7 will
have to be designed. Thus, future work will be centered on the
synthesis of such avidity-improved systems and their evaluation
in dedicated cellular infection assays.
■ MATERIALS AND METHODS
Compounds. The GlcNAc-sulfated derivatives (Figure 2A) were
purchased from Dextra Laboratories.
DC-SIGN and Langerin ECD Production and Puriﬁcation.WT
and mutated recombinant forms of DC-SIGN and langerin
extracellular domain (DC-SIGN ECD and Lg-ECD respectively)
were produced and puriﬁed as described previously.41,49
Crystallization. Crystals of Lg-CRD were grown from a sample of
Lg-ECD by the hanging-drop vapor-diﬀusion method at 293 K with a
protein/reservoir drop ratio of 1:1, at a protein concentration of 15 mg
mL−1 in 25 mM Tris-HCl at pH 8, 150 mM NaCl, and 4 mM CaCl2
and a reservoir containing 100 mM HEPES at pH 7, 100 mM MgCl2,
150 mM NaCl, and 20% PEG 3350 supplemented or not with 70 mM
europium dipicolinate. The use of this lanthanide complex was
motivated by the aim to crystallize the full-length langerin ECD
protein by inducing interactions between the complex and arginine
residues to promote crystal contacts.50 Crystals appeared after 2
months with the typical Lg-CRD crystal shape and dimension
described previously.51 In drop proteolysis, by traces of proteases, of
Lg-ECD between the CRD and the Neck domain of langerin account
for this phenomenon. This was conﬁrmed by evaluation of the space
group and the cell dimension.
For Lg-CRD/GlcNS6S complex preparation, crystals were ﬁrst
washed in 100 mM HEPES at pH 7, 100 mM MgCl2, 150 mM NaCl,
and 35% PEG 3350 for cryoprotection and, second, soaked and
equilibrated by vapor diﬀusion over 1 h in 1 μL of the previous
solution supplemented with 10 mM GlcNS6S. Crystals were directly
ﬂash frozen in liquid nitrogen.
Data Collection, Processing, and Structure Determination.
X-ray diﬀraction data were collected in the BM30a beamline at the
ESRF Grenoble using an ADSC Q315r detector. The crystals was
diﬀracted with a wavelength of 0.979 Å, exposition time of 20 s/
images, 200 images with an angular step of 0.5°, and a detector
distance of 220 mm. Data processing is described in the SI Structural
Analysis section. Coordinates and associated structure factors have
been deposited in the PDB database, code: 5g6u.
Surface Plasmon Resonance Analysis. Surface plasmon
resonance experiments were performed on a Biacore 3000 using a
CM4 chip, functionalized at 5 μL/min. Fc1 and Fc3 were prepared as
reference surfaces. Flow cells (Fc) from 1 to 4 were activated with 50
μL of a 0.2 M EDC/0.05 M NHS mixture. After this step, Fc1 to Fc4
were respectively functionalized with bovine serum albumin (BSA)
Figure 6. ITC and SPR analysis of glycomimetic 7 titration to DC-SIGN ECD. (A) Titration of glycomimetic 7 at 4.7 mM to DC-SIGN ECD (566
μM). Upper panel shows the titration thermogram and lower panel, the data integration with ﬁtted curves (1:1 binding model). (B) Titration of
glycomimetic 7 onto DC-SIGN ECD functionalized surface. Upper panel shows reference-subtracted sensorgrams of increasing concentrations of 7
and lower panel, the steady state binding analysis (1:1 binding model).
ACS Chemical Biology Articles
DOI: 10.1021/acschembio.7b00958
ACS Chem. Biol. 2018, 13, 600−608
605
and mannosylated bovine serum albumin (BSA-Man, BSA-manα1−
3[manα1−6]man, Dextra laboratories, 60 μg mL−1). Then remaining
activated groups of both cells were blocked with 30 μL of 1 M
ethanolamine. After blocking, the four Fc’s were treated with 5 μL of
10 mM HCl to remove unspeciﬁc bound protein and 5 μL of 50 mM
EDTA to expose the surface to a regeneration protocol. Finally, 238
RU and 1847 RU of BSA and BSA-Man were respectively immobilized
on Fc1 and Fc2.
For inhibition studies, on Fc2 or Fc4, 20 μM of DC-SIGN ECD or
15 μM of langerin ECD, respectively, are mixed with increasing
concentrations of inhibiting compounds that were prepared in a
running buﬀer composed of 25 mM Tris at pH 8, 150 mM NaCl, 4
mM CaCl2, and 0.005% P20 surfactant, and 13 μL of each sample was
injected onto the surfaces at a 5 μL/min ﬂow rate. The resulting
sensorgrams were reference surface corrected.
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The DC-SIGN binding responses were extracted from sensorgrams,
converted to percent residual activity values (y), which were plotted
against corresponding compound concentration. The four-parameter
logistic model (eq 1), available in the BiaEval software, was ﬁtted to
the plots, and the IC50 values were calculated, from eq 2, using the
values of ﬁtted parameters (Rhi, Rlo, A1, and A2). The software is able to
ﬁt and to calculate an IC50 even if the 50% inhibition is not observed as
it is in the case for one of the ligands in Figure 2.
Isothermal Titration Calorimetric analysis. ITC experiments
were performed at 25 °C using a TA Instrument Nano Isothermal
Titration Calorimeter Low Volume (Nano ITC LV) with a 190 μL cell
volume. Compound 7 and DC-SIGN ECD were prepared in 25 mM
Tris at pH 8, 150 mM NaCl, and 4 mM CaCl2. The compound was
stepwise injected (1.03 μL) into DC-SIGN solution using 5 min
intervals between injections. Then, 566 μM of monomeric DC-SIGN
ECD and 0.47 mM compound concentrations were used. The blank
titrations (compounds to buﬀer) were done for subtraction of dilution
heat from the integrated data. A one-site binding model was ﬁt to the
data (nanoAnalyse 2.20 TA), yielding association constants (KA) and
binding enthalpies (ΔH). The free energy changes (ΔG) and entropy
(ΔS) were calculated using the following equation:
Δ = Δ − Δ = −G H T S RT Kln A
where T is the absolute temperature and R = 8.314.
Synthesis. The 6-modiﬁed pseudodisaccharides 3−7 were
synthesized starting from 6-azidomannose tetra-O-benzoate following
procedures previously established for 1 and 2. Full details are collected
in the Supporting Information.
NMR Analysis. All NMR experiments were performed on a Bruker
Avance DRX 500 MHz spectrometer equipped with a 5 mm inverse
triple-resonance probe. All the samples were dissolved in 550 μL of
buﬀer D2O (150 mM NaCl, 4 mM CaCl2, 25 mM d-Tris, pD 7.2) with
a ligand concentration of 2 mM for free ligand analysis. For the
experiments in the presence of receptor 19 or 9.5 μM of DC-SIGN
and 1.0 mM of the ligand were used. The pD was adjusted to 7.2 in all
samples. STD NMR experiments were carried out at 25 °C. For
protein saturation, a train of Gaussian shaped pulses with a length of
49 ms, an interpulse delay of 1 ms, and an attenuation of 50 dB was
used. The unwanted broad resonance signals of the protein were
removed by use of a spin lock pulse of 15 ms prior to acquisition. For
suppression of the water signal, the WATERGATE scheme (3−9−19)
was employed. The on-resonance frequency was set to −1 ppm,
whereas the oﬀ-resonance frequency was set to 40 ppm, interleaved
recorded. Reference experiments were carried out to conﬁrm the
absence of direct irradiation of the ligand. Saturation times to obtain
the build-up curves were 0.5, 1, 1.5, 2, 3, and 4 s. Additional
experimental details are given in the Supporting Information.
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(23) Theṕaut, M., Guzzi, C., Sutkeviciute, I., Sattin, S., Ribeiro-Viana,
R., Varga, N., Chabrol, E., Rojo, J., Bernardi, A., Angulo, J., Nieto, P.
M., and Fieschi, F. (2013) Structure of a Glycomimetic Ligand in the
Carbohydrate Recognition Domain of C-type Lectin DC-SIGN.
Structural Requirements for Selectivity and Ligand Design. J. Am.
Chem. Soc. 135, 2518−2529.
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